Akebia Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
The offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-223585) previously filed with the
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
Certain statements contained in this press release, including those relating to the expected proceeds from the offering and the expected closing of the offering, are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with the consummation of the proposed offering, the impact of the coronavirus 2 (SARS-CoV-2) pandemic on our company, general economic conditions and other risks identified from time to time in the reports Akebia files with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-301057150.html